Multi-omics Approaches to Precision Therapy in Type 2 Diabetes

Type 2 diabetes (T2D) is a complex, heterogeneous metabolic disorder characterized by diverse genetic, epigenetic, and environmental determinants that influence disease progression and therapeutic response. Despite the availability of multiple pharmacological interventions, interindividual variability in treatment outcomes remains a major clinical challenge. Precision medicine approaches, driven by advances in multi-omics technologies, offer new opportunities to stratify patients and optimize therapeutic strategies.

This Special Issue seeks to explore how integrated multi-omics approaches, including genomics, transcriptomics, proteomics, metabolomics, and epigenomics, can inform precision therapy in T2D. Particular emphasis will be placed on the identification and repurposing of established and widely used drugs, leveraging molecular profiling to uncover novel mechanisms of action, predictive biomarkers, and patient-specific treatment responses.

The repositioning of “old” drugs, such as metformin, sulfonylureas, thiazolidinediones, and other non-diabetes medications with metabolic effects, represents a cost-effective and rapidly translatable strategy. Multi-omics data can provide critical insights into drug response variability, off-target effects, and previously unrecognized therapeutic pathways, thereby enabling more precise and individualized treatment regimens.

We invite submissions that address, but are not limited to, the following themes:

• Multi-omics profiling to stratify T2D subtypes and guide therapy selection
• Systems biology and integrative analyses linking omics data to drug response
• Mechanistic insights into the action of established antidiabetic drugs
• Repurposing of non-traditional drugs for glycemic control and metabolic regulation
• Biomarker discovery for predicting therapeutic efficacy and adverse effects
• Clinical and translational studies applying omics-guided treatment strategies
• Real-world evidence and clinical trials incorporating multi-omics data
• Computational and AI-driven approaches for multi-omics integration in T2D

We particularly encourage interdisciplinary studies that bridge basic science, clinical research, and computational modeling, as well as contributions that demonstrate clear translational potential. By focusing on both cutting-edge omics technologies and the strategic reuse of established therapeutics, this special issue aims to accelerate the development of accessible and effective precision medicine approaches for T2D.

Please note that the manuscript submission deadline is flexible, if you require an extension or have any other question, do not hesitate to contact us at the Publishing Office.

Article types and fees

This Special Issue accepts the following article types, unless otherwise specified in the Special Issue description:

• Brief Research Report
• Editorial
• Letter to the Editor
• Mini Review
• Original Research
• Perspective
• Review
• Systematic Review
• Technology and Code

Articles that are accepted for publication by our external editors following rigorous peer review incur a publishing fee charged to Authors, institutions, or funders.

Article types

This Special Issue accepts the following article types, unless otherwise specified in the Special Issue description:

• Brief Research Report
• Editorial
• Letter to the Editor
• Mini Review
• Original Research
• Perspective
• Review
• Systematic Review
• Technology and Code

Keywords: Type 2 Diabetes, Multi-omics, Precision Medicine, Drug Repurposing, Biomarker Discovery